About
About Baolingbao Biology Co.,Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, allulose, and maltotetrasaccharide; dietary fiber comprising polydextrose and resistant dextrin; modified, waxy corn, and corn starch products; starch sugar, which includes maltodextrose, high fructose syrup, solid corn syrup, maltodextrin, and glucose syrup; and animal nutrition products, such as baolekang and fubaokang. It also provides health plans comprising low sugar and calorie; nutritional fortification; microecological regulation; exclusive customization; texture optimization; medical aesthetics and daily chemical products; and antibiotic-reduced farming. The company's products are used in dairy products, drinks, snack food, health products and dietary supplements, candy, special dietary food, chemicals, and animal nutrition applications. It exports its products. The company was founded in 1997 and is based in Yucheng, China.
Research context
Baolingbao Biology Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Baolingbao Biology Co.,Ltd is currently in a long term downtrend where the price is trading 11.3% below its 200 day moving average.
From a valuation standpoint, the stock is 80.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
Baolingbao Biology Co.,Ltd's total revenue rose by 18.7% to $526M since the same quarter in the previous year.
Its net income has dropped by 34.7% to $10M since the same quarter in the previous year.
Finally, its free cash flow grew by 92.6% to $118M since the same quarter in the previous year.
Based on the above factors, Baolingbao Biology Co.,Ltd gets an overall score of 3/5.